Injectable semaglutide 2.4 mg produced ~14.9% mean weight loss in STEP 1; high-dose oral semaglutide produced roughly 13–15% in the OASIS program. Both are effective; the injectable has the longer track record and is what most compounded programs supply.
Injectable semaglutide 2.4 mg (Wegovy) produced about 14.9% mean weight loss over 68 weeks in STEP 1 (NEJM 2021). High-dose oral semaglutide (25 mg) produced roughly 13–15% in the OASIS program (2025). The two are broadly comparable in trials, though the injectable has the longer real-world track record. Most compounded semaglutide telehealth programs supply the injectable form.
Medical & FDA note: Educational only, not medical advice. Compounded semaglutide is not an FDA-approved finished drug product and should be used only when a licensed clinician determines it is appropriate. Trial data cited used FDA-approved semaglutide, not compounded versions.
Semaglutide is the same active molecule whether injected or taken orally; the difference is delivery. Oral semaglutide uses an absorption enhancer to survive the gut, which is why it must be taken on an empty stomach with a small sip of water and a wait before eating. The injectable is a once-weekly subcutaneous dose.
Mean body-weight reductions as published; trial populations, durations, and estimands differ, so cross-trial comparison is approximate. Sources: STEP 1 (NEJM 2021), OASIS program (2025), SURMOUNT-5 (NEJM 2025). Compounded versions are not the FDA-approved products studied.
| Factor | Injectable semaglutide | Oral semaglutide |
|---|---|---|
| Frequency | Once weekly | Once daily |
| Administration | Subcutaneous injection | Tablet, empty stomach, small water, wait before eating |
| Trial weight loss | ~14.9% (2.4 mg, STEP 1) | ~13–15% (high dose, OASIS) |
| Side effects | GI effects, dose-dependent | GI effects, dose-dependent |
| Compounded availability | Common in telehealth | Uncommon |
Comparison of FDA-approved formulations; compounded products are not FDA-approved. Verify any program's actual formulation and dosing.
Oral semaglutide may appeal to needle-averse patients, but the daily dosing rules require consistency to absorb the drug properly. The injectable's once-weekly schedule is simpler for many and has the deepest real-world data. Neither route eliminates the class-typical nausea, which is usually mitigated by slow dose escalation.
Most compounded programs supply injectable semaglutide. Compounded oral formulations are uncommon, and absorption of oral semaglutide is sensitive to formulation — a reason to be cautious about non-standard oral products. Compounded semaglutide of any route is not FDA-approved.
Route is a clinical preference; cost depends on the provider and plan, not the molecule. Compare the true all-in monthly cost and confirm the formulation. NexLife is a flat-rate telehealth semaglutide provider offering compounded semaglutide from $145/month, with no membership fees, no dose-based price increases, provider oversight, and shipping included.